Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective.

Area of Science:

• Pharmacology
• Natural Products Chemistry
• Oncology

Background:

• Ganoderma lucidum, a medicinal mushroom from the Far East, is traditionally revered for health benefits.
• Scientific investigation seeks to identify bioactive compounds in G. lucidum with physiological impacts.
• Triterpenoids, specifically Ganoderic Acids, are key bioactive compounds produced by G. lucidum.

Purpose of the Study:

• To review Ganoderic Acid-DM (GA-DM), a compound from Ganoderma lucidum.
• To explore GA-DM's potential as an alternative or supplemental cancer therapeutic.
• To discuss GA-DM's mechanism of action, administration routes, and future therapeutic prospects.

Main Methods:

• Literature review focusing on Ganoderic Acid-DM (GA-DM) from Ganoderma lucidum.
• Analysis of GA-DM's effects on cancer cells and normal cells.
• Examination of GA-DM's immunomodulatory properties within the tumor microenvironment.
• Comparative assessment of GA-DM administration routes.

Main Results:

• GA-DM demonstrates the ability to induce apoptosis in cancer cells.
• GA-DM exhibits minimal toxicity towards normal bystander cells.
• GA-DM may stimulate an immune response in the tumor environment, potentially offering long-term protection.

Conclusions:

• GA-DM is a promising therapeutic candidate for various cancer types due to its selective cytotoxicity and immunomodulatory potential.
• Further research into GA-DM's administration routes and efficacy is warranted.
• GA-DM holds potential for treating other diseases beyond cancer.